Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Company preparing to initiate comprehensive Phase 3 program for chronic cough in patients with idiopathic pulmonary fibrosis in first half of 2026 Company...

What's Your Reaction?











